Literature DB >> 26048664

Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.

Verena Niederberger1, Katharina Marth2, Julia Eckl-Dorna3, Margarete Focke-Tejkl4, Milena Weber4, Wolfgang Hemmer5, Uwe Berger3, Angela Neubauer6, Frank Stolz6, Rainer Henning6, Rudolf Valenta4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26048664      PMCID： PMC6536382          DOI： 10.1016/j.jaci.2015.03.034

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  10 in total

1.  EAACI/GA2LEN position paper: present status of the atopy patch test.

Authors:  K Turjanmaa; U Darsow; B Niggemann; F Rancé; T Vanto; T Werfel
Journal:  Allergy       Date:  2006-12       Impact factor: 13.146

Review 2.  Update on the current status of peptide immunotherapy.

Authors:  Mark Larché
Journal:  J Allergy Clin Immunol       Date:  2007-04       Impact factor: 10.793

3.  Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.

Authors:  L Winther; H J Malling; H Mosbech
Journal:  Allergy       Date:  2000-09       Impact factor: 13.146

Review 4.  Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.

Authors:  R Valenta; R Campana; K Marth; M van Hage
Journal:  J Intern Med       Date:  2012-08       Impact factor: 8.989

5.  Heterogeneity of commercial timothy grass pollen extracts.

Authors:  M Focke; K Marth; S Flicker; R Valenta
Journal:  Clin Exp Allergy       Date:  2008-06-28       Impact factor: 5.018

6.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

7.  Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man.

Authors:  Ines Pree; Jürgen Reisinger; Margit Focke; Susanne Vrtala; Gabrielle Pauli; Marianne van Hage; Oliver Cromwell; Elisabeth Gadermaier; Cornelia Egger; Norbert Reider; Friedrich Horak; Rudolf Valenta; Verena Niederberger
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

8.  Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.

Authors:  L Jacobsen; B Niggemann; S Dreborg; H A Ferdousi; S Halken; A Høst; A Koivikko; L A Norberg; E Valovirta; U Wahn; C Möller
Journal:  Allergy       Date:  2007-08       Impact factor: 13.146

9.  Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Authors:  Margarete Focke-Tejkl; Milena Weber; Katarzyna Niespodziana; Angela Neubauer; Hans Huber; Rainer Henning; Gottfried Stegfellner; Bernhard Maderegger; Martina Hauer; Frank Stolz; Verena Niederberger; Katharina Marth; Julia Eckl-Dorna; Richard Weiss; Josef Thalhamer; Katharina Blatt; Peter Valent; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2014-11-13       Impact factor: 10.793

10.  Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides.

Authors:  Céline Pellaton; Yannick Perrin; Caroline Boudousquié; Nathalie Barbier; Jacqueline Wassenberg; Giampietro Corradin; Anne-Christine Thierry; Régine Audran; Christophe Reymond; François Spertini
Journal:  Clin Transl Allergy       Date:  2013-06-01       Impact factor: 5.871
  10 in total
  20 in total

Review 1.  [Innovative forms of specific immunotherapy].

Authors:  P Zieglmayer
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

Review 2.  Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.

Authors:  Rudolf Valenta; Raffaela Campana; Margit Focke-Tejkl; Verena Niederberger
Journal:  J Allergy Clin Immunol       Date:  2016-02       Impact factor: 10.793

3.  Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Authors:  Raffaela Campana; Katharina Moritz; Katharina Marth; Angela Neubauer; Hans Huber; Rainer Henning; Katharina Blatt; Gregor Hoermann; Tess M Brodie; Alexandra Kaider; Peter Valent; Federica Sallusto; Stefan Wöhrl; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2015-10-28       Impact factor: 10.793

4.  Clustering of conformational IgE epitopes on the major dog allergen Can f 1.

Authors:  Mirela Curin; Milena Weber; Gerhard Hofer; Danijela Apostolovic; Walter Keller; Renate Reininger; Ines Swoboda; Susanne Spitzauer; Margit Focke-Tejkl; Marianne van Hage; Rudolf Valenta
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

Review 5.  Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.

Authors:  Mirela Curin; Musa Khaitov; Alexander Karaulov; Leyla Namazova-Baranova; Raffaela Campana; Victoria Garib; Rudolf Valenta
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-09       Impact factor: 4.806

Review 6.  Molecular aspects of allergens in atopic dermatitis.

Authors:  Raffaela Campana; Sheron Dzoro; Irene Mittermann; Elena Fedenko; Olga Elisyutina; Musa Khaitov; Alexander Karaulov; Rudolf Valenta
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-08

7.  CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells.

Authors:  Regina Selb; Julia Eckl-Dorna; Alina Neunkirchner; Klaus Schmetterer; Katharina Marth; Jutta Gamper; Beatrice Jahn-Schmid; Winfried F Pickl; Rudolf Valenta; Verena Niederberger
Journal:  J Allergy Clin Immunol       Date:  2016-05-09       Impact factor: 10.793

8.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Authors:  Petra Zieglmayer; Margarete Focke-Tejkl; René Schmutz; Patrick Lemell; René Zieglmayer; Milena Weber; Renata Kiss; Katharina Blatt; Peter Valent; Frank Stolz; Hans Huber; Angela Neubauer; Anette Knoll; Friedrich Horak; Rainer Henning; Rudolf Valenta
Journal:  EBioMedicine       Date:  2016-08-20       Impact factor: 8.143

9.  A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

Authors:  R Mösges; E M Kasche; E Raskopf; J Singh; L Sohlich; A Astvatsatourov; K Shah-Hosseini; S Pirotton; L Haazen; S R Durham; T Legon; G Zadoyan; M H Shamji
Journal:  Allergy       Date:  2017-12-22       Impact factor: 13.146

10.  Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.

Authors:  Carolin Cornelius; Katrin Schöneweis; Fanny Georgi; Milena Weber; Verena Niederberger; Petra Zieglmayer; Katarzyna Niespodziana; Michael Trauner; Harald Hofer; Stephan Urban; Rudolf Valenta
Journal:  EBioMedicine       Date:  2016-08-08       Impact factor: 8.143
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.